Compare Stocks: RARE, CYTK, KRYS, and RDY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$77.13	$78.75	$32.89 ▼ $88.31	$9.60B	0.42	1.72 million shs	1.58 million shs
KRYS Krystal Biotech	$341.12	$339.70	$130.50 ▼ $382.54	$10.06B	0.53	594,653 shs	488,442 shs
RARE Ultragenyx Pharmaceutical	$24.91	$27.68	$18.29 ▼ $39.89	$2.45B	0.35	1.89 million shs	1.54 million shs
RDY Dr. Reddy's Laboratories	$11.85 0.0%	$13.32	$11.36 ▼ $15.67	$9.89B	0.29	2.99 million shs	3.01 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-4.47%	-10.82%	+21.75%	+110.22%
KRYS Krystal Biotech	0.00%	+1.77%	-9.05%	+28.22%	+117.30%
RARE Ultragenyx Pharmaceutical	0.00%	-7.40%	-25.58%	+0.57%	-12.41%
RDY Dr. Reddy's Laboratories	0.00%	+0.59%	-17.67%	-13.70%	-15.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYTK Cytokinetics	$77.13	$78.75	$32.89 ▼ $88.31	$9.60B	0.42	1.72 million shs	1.58 million shs
KRYS Krystal Biotech	$341.12	$339.70	$130.50 ▼ $382.54	$10.06B	0.53	594,653 shs	488,442 shs
RARE Ultragenyx Pharmaceutical	$24.91	$27.68	$18.29 ▼ $39.89	$2.45B	0.35	1.89 million shs	1.54 million shs
RDY Dr. Reddy's Laboratories	$11.85 0.0%	$13.32	$11.36 ▼ $15.67	$9.89B	0.29	2.99 million shs	3.01 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYTK Cytokinetics	0.00%	-4.47%	-10.82%	+21.75%	+110.22%
KRYS Krystal Biotech	0.00%	+1.77%	-9.05%	+28.22%	+117.30%
RARE Ultragenyx Pharmaceutical	0.00%	-7.40%	-25.58%	+0.57%	-12.41%
RDY Dr. Reddy's Laboratories	0.00%	+0.59%	-17.67%	-13.70%	-15.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYTK Cytokinetics	2.95	Moderate Buy	$99.90	29.52% Upside
KRYS Krystal Biotech	2.83	Moderate Buy	$360.67	5.73% Upside
RARE Ultragenyx Pharmaceutical	2.83	Moderate Buy	$58.41	134.49% Upside
RDY Dr. Reddy's Laboratories	1.67	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest RARE, CYTK, KRYS, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2026	RDY Dr. Reddy's Laboratories	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/17/2026	CYTK Cytokinetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	KRYS Krystal Biotech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$364.00 ➝ $396.00
7/13/2026	KRYS Krystal Biotech	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$474.00
7/9/2026	RARE Ultragenyx Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	CYTK Cytokinetics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$119.00 ➝ $117.00
7/7/2026	RARE Ultragenyx Pharmaceutical	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $40.00
7/1/2026	KRYS Krystal Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
6/29/2026	CYTK Cytokinetics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$69.00 ➝ $115.00
6/24/2026	RARE Ultragenyx Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$100.00 ➝ $118.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYTK Cytokinetics	$105.82M	90.70	N/A	N/A	($5.39) per share	-14.31
KRYS Krystal Biotech	$389.13M	25.84	$7.29 per share	46.79	$42.06 per share	8.11
RARE Ultragenyx Pharmaceutical	$673M	3.65	N/A	N/A	($0.83) per share	-30.01
RDY Dr. Reddy's Laboratories	$3.58B	2.76	$0.85 per share	13.99	$4.86 per share	2.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYTK Cytokinetics	-$784.96M	-$6.84	N/A	N/A	N/A	-784.02%	N/A	-52.86%	8/6/2026 (Estimated)
KRYS Krystal Biotech	$204.83M	$7.48	45.60	36.68	N/A	53.92%	19.25%	17.62%	8/3/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$6.11	N/A	N/A	N/A	-91.03%	-1,024.42%	-45.78%	8/4/2026 (Estimated)
RDY Dr. Reddy's Laboratories	$456M	$0.44	26.92	20.08	2.38	10.15%	9.49%	6.32%	N/A

Latest RARE, CYTK, KRYS, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CYTK Cytokinetics	-$1.63	N/A	N/A	N/A	$17.59 million	N/A
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.21	N/A	N/A	N/A	$183.08 million	N/A
8/3/2026	Q2 2026	KRYS Krystal Biotech	$1.73	$1.79	+$0.06	$1.79	$121.81 million	$119.22 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million
5/12/2026	Q4 25/26	RDY Dr. Reddy's Laboratories	$0.09	$0.06	-$0.03	-$0.03	$886.58 million	$852.55 million
5/5/2026	Q1 2026	CYTK Cytokinetics	-$1.67	-$1.67	N/A	-$1.67	$8.52 million	$19.36 million
5/5/2026	Q1 2026	RARE Ultragenyx Pharmaceutical	-$1.4878	-$1.84	-$0.3522	-$1.84	$158.19 million	$136.00 million
5/4/2026	Q1 2026	KRYS Krystal Biotech	$1.45	$1.83	+$0.38	$1.83	$112.11 million	$116.36 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.51%	+6.96%	13.64%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYTK Cytokinetics	N/A	4.21	4.21
KRYS Krystal Biotech	N/A	9.46	9.06
RARE Ultragenyx Pharmaceutical	N/A	2.02	1.85
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYTK Cytokinetics	N/A
KRYS Krystal Biotech	86.29%
RARE Ultragenyx Pharmaceutical	97.67%
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
CYTK Cytokinetics	2.60%
KRYS Krystal Biotech	13.10%
RARE Ultragenyx Pharmaceutical	5.20%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYTK Cytokinetics	250	124.43 million	121.20 million	Optionable
KRYS Krystal Biotech	210	29.48 million	25.62 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.49 million	93.37 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.97 million	Optionable

RARE, CYTK, KRYS, and RDY Headlines

Recent News About These Companies

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

July 31 at 10:07 AM | prnewswire.com

Royal Bank of Canada Buys 434,805 Shares of Dr. Reddy's Laboratories Ltd $RDY

July 31 at 5:27 AM | marketbeat.com

Dr. Reddy's Laboratories Ltd $RDY Shares Sold by Lazard Asset Management LLC

July 30, 2026 | marketbeat.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)

July 29, 2026 | globenewswire.com

Dr Reddys Laboratories Ltd (RDY)

July 28, 2026 | insidermonkey.com

Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...

July 28, 2026 | finance.yahoo.com

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)

July 28, 2026 | businesswire.com

Renaissance Technologies LLC Sells 395,400 Shares of Dr. Reddy's Laboratories Ltd $RDY

July 26, 2026 | marketbeat.com

Wall Street Zen Downgrades Dr. Reddy's Laboratories (NYSE:RDY) to Sell

July 25, 2026 | americanbankingnews.com

Dr. Reddy's Laboratories (NYSE:RDY) Downgraded by Wall Street Zen to Sell

July 25, 2026 | marketbeat.com

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

July 24, 2026 | prnewswire.com

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

July 24, 2026 | youtube.comY

U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

July 23, 2026 | cnbc.com

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

July 23, 2026 | zacks.com

Why Dr. Reddy's sank: Profit plunge, semaglutide setback and Trump's tariff threat

July 22, 2026 | msn.com

Dr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call Transcript

July 22, 2026 | seekingalpha.com

Doctor Reddy’s: Fiscal Q1 Earnings Snapshot

July 22, 2026 | wtop.comW

Dr. Reddy's falls after Q1 results amid Trump’s tariff threat

July 22, 2026 | seekingalpha.com

Dr. Reddy's Laboratories Q1 Earnings Call Highlights

July 22, 2026 | marketbeat.com

Dr. Reddy's Laboratories (NYSE:RDY) Issues Quarterly Earnings Results

July 22, 2026 | marketbeat.com

Dr. Reddy's Laboratories (NYSE:RDY) Sets New 12-Month Low - Time to Sell?

July 22, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RARE, CYTK, KRYS, and RDY Company Descriptions

Cytokinetics NASDAQ:CYTK

$77.13 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$77.10 -0.02 (-0.03%)

As of 07/31/2026 07:34 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Krystal Biotech NASDAQ:KRYS

$341.12 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$339.40 -1.72 (-0.50%)

As of 07/31/2026 07:40 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Ultragenyx Pharmaceutical NASDAQ:RARE

$24.91 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$25.57 +0.66 (+2.65%)

As of 07/31/2026 07:48 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Dr. Reddy's Laboratories NYSE:RDY

$11.84 -0.01 (-0.04%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$11.85 +0.00 (+0.04%)

As of 07/31/2026 07:34 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RARE, CYTK, KRYS, and RDY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RARE, CYTK, KRYS, and RDY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RARE, CYTK, KRYS, and RDY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RARE, CYTK, KRYS, and RDY Company Descriptions

Cytokinetics NASDAQ:CYTK

Krystal Biotech NASDAQ:KRYS

Ultragenyx Pharmaceutical NASDAQ:RARE

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RARE, CYTK, KRYS, and RDY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RARE, CYTK, KRYS, and RDY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RARE, CYTK, KRYS, and RDY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RARE, CYTK, KRYS, and RDY Company Descriptions

Cytokinetics NASDAQ:CYTK

Krystal Biotech NASDAQ:KRYS

Ultragenyx Pharmaceutical NASDAQ:RARE

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools